
What does it take to build a biotech that can turn a scientific breakthrough into lasting impact for patients? Our CEO @SamBarrell1 moderated this insightful panel discussion at London Life Sciences Week.

Self-funded medical research organisation with one clear purpose – transforming the lives of people living with rare diseases and drug-resistant infections.

What does it take to build a biotech that can turn a scientific breakthrough into lasting impact for patients? Our CEO @SamBarrell1 moderated this insightful panel discussion at London Life Sciences Week.

Scientific innovation is crucial, but it’s only part of the #AntimicrobialResistance response. This #WAAW2026, find out how LifeArc is playing our part to address this complex global health challenge: lifearc.org/2026/scientific-…

We’re pleased to continue our support for @UKMNDRI alongside @MNDoddie5 and @mndassoc Together, we’re committing £5m over the next 5 years, helping to build on the progress already made and move promising research towards potential new treatments for people living with MND.
We're supporting the next phase of the @UKMNDRI as part of a new £5 million co-funded commitment alongside @mndassoc and @lifearc1 over the next 5 years, to accelerate the search for effective treatments for MND. See more details here👉myname5doddie.co.uk/news-and…

This week, our CEO Sam Barrell joined a panel at the @britishlibrary to discuss what’s next for health innovation in the Knowledge Quarter, discussing how stronger collaboration can help close gaps and turn more promising science into patient impact.



In therapeutic development, a useful workshop does not close a conversation – it creates a stronger starting point for the next one. We're sharing 7 lessons from our childhood cancer workshops. Read them all: t.ly/oMPZi

We’re backing a major study analysing 80,000+ UK Biobank blood samples to help researchers better understand Parkinson’s, Alzheimer’s and rare dementias. 🔗 Read more about the new study: lifearc.org/2026/lifearc-bac…

Open collaboration depends on trust. Creating space to share knowledge while respecting sensitive information helps enable open discussion without compromising confidentiality. We're sharing 7 lessons from our childhood cancer workshops. Read them all: t.ly/oMPZi

Raremap has been growing – we now have 160 organisations in the community! If you work in rare disease, request to be added now: raremap.co.uk/join/

The Future for Rare report, published today by @GeneticAll_UK, calls for a renewed focus on data, diagnosis, coordinated care, and the appointment of a rare disease lead in each UK country accountable for turning ambition into action. Read it now 👉geneticalliance.org.uk/futur…

DSRCT is an extremely rare and aggressive cancer affecting children and young adults. We brought together researchers, clinicians and patient advocates to identify promising opportunities for future treatments. 📄 Read the findings: nature.com/articles/s41416-0…

Knowing what not to pursue can be as valuable as knowing what to prioritise. Our workshops showed the value of making clear choices on what should and shouldn't move forward, and why. Read 7 key lessons we've shared from our childhood cancer workshops: t.ly/oMPZi

Meaningful patient involvement in rare disease research doesn't happen by chance. It requires funding, infrastructure, recognition and commitment. Our new co-authored peer-reviewed commentary explored how PPIE can be embedded across the research pathway: t.ly/vggqd

How do patients feel about their information being used to advance scientific research? It’s an important question, and one which you can explore further in this easy-to-read summary from our Translational Science Summit, by Readable Research: readableresearch.com/lifearc…

For any workshop, the most important work often happens before the meeting starts. Preparation creates a common foundation of understanding and helps drive engagement in the meeting itself. Read the 7 lessons learned from our childhood cancer workshops: t.ly/oMPZi